Allow Medicare and Medicaid to negotiate drug prices.

by allowing Medicare, Medicaid to negotiate drug prices

Schrier commits to enabling Medicare and Medicaid drug-price negotiations.

Dr. Kim Schrier Doubles Down on Healthcare in First Two Ads + Comprehensive Reform Proposal | Kim Schrier
campaign · press_release · model gpt-5.4-mini

CMS says the Medicare Drug Price Negotiation Program has negotiated maximum fair prices for selected drugs, including the 10 drugs whose MFPs went into effect on January 1, 2026, and that the program will continue with later cycles in 2026 and 2027.

Confirms Medicare drug-price negotiation is now operational and producing negotiated prices, which is concrete delivery on the Medicare part of the promise.

partial same_term

Selected Drugs and Negotiated Prices | CMS
secondary · model gpt-5.4-mini · confidence 96%

CMS says the GENEROUS Model aims to ensure fair and reasonable drug prices for Medicaid through CMS-led negotiations with drug manufacturers, with lower prices for participating state Medicaid programs.

Shows a new federal Medicaid drug-pricing negotiation model has been launched, but it is voluntary and model-based rather than a broad statutory Medicaid negotiation right, so it is only partial progress on the Medicaid portion.

partial same_term A for effort

GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model | CMS
secondary · model gpt-5.4-mini · confidence 88%

Schrier’s issues page says the Inflation Reduction Act is law and that it gives Medicare the power to negotiate lower drug prices and cap Medicare out-of-pocket medication costs.

Her current official issue page ties her position to the enacted Medicare negotiation change, reinforcing that the Medicare portion has been delivered while not indicating a comparable Medicaid statutory change.

partial same_term

Issues | Representative Kim Schrier
secondary · model gpt-5.4-mini · confidence 79%